SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

Abstract

Congenital infection of SARS-CoV-2 appears to be exceptionally rare despite many cases of COVID-19 during pregnancy. Robust proof of placental infection requires demonstration of viral localization within placental tissue. Only two of the few cases of possible vertical transmission have demonstrated placental infection. None have shown placental expression of the ACE2 or TMPRSS2 protein, both required for viral infection. We examined 19 COVID-19 exposed placentas for histopathologic findings, and for expression of ACE2, and TMPRSS2 by immunohistochemistry. Direct placental SARS-CoV-2 expression was studied by two methods—nucleocapsid protein expression by immunohistochemistry, and RNA expression by in situ hybridization. ACE2 membranous expression in the syncytiotrophoblast (ST) of the chorionic villi is predominantly in a polarized pattern with expression highest on the stromal side of the ST. In addition, cytotrophoblast and extravillous trophoblast express ACE2. No ACE2 expression was detected in villous stroma, Hofbauer cells, or endothelial cells. TMPRSS2 expression was only present weakly in the villous endothelium and rarely in the ST. In 2 of 19 cases, SARS-CoV-2 RNA was present in the placenta focally in the ST and cytotrophoblast. There was no characteristic histopathology present in our cases including the two placental infections. We found that the placenta is capable of being infected but that this event is rare. We propose one explanation could be the polarized expression of ACE2 away from the maternal blood and pronounced paucity of TMPRSS2 expression in trophoblast.

Introduction

SARS-CoV-2 is an enveloped single positive stranded RNA virus responsible for the current pandemic of severe respiratory infections worldwide termed COVID-19 [1]. SARS-CoV-2 infects tissues via its receptor, ACE2, and entry into cells requires spike protein cleavage by the serine protease TMPRSS2 [2]. Although many reports of COVID-19 in pregnancy describe complications, such as preterm birth [3], vertical transmission is apparently extremely rare [4, 5, 6, 7, 8, 9, 10]. Few reports of pregnancy and COVID-19 address placental infection rigorously and, to date, only two reports have demonstrated direct viral infection of the placenta [9, 10].

Although the villous syncytiotrophoblast (ST), which lines the surface of the placenta, provides a good barrier to placental infection, viral infections of the placenta do occur, and vertical transmission to the fetus has been demonstrated by many viruses most common are DNA viruses including CMV and HSV [11]. These placental viral infections typically show a histological footprint of chronic inflammation in/of the villi (chronic villitis) or the intervillous space (intervillositis), or both [11]. Infection occurs via either receptors on the villous ST or breaks in the villous trophoblast covering of the villous stroma allowing for infection of stromal cells particularly resident macrophages called Hofbauer cells [12]. Infection of extravillous trophoblast (EVT) has also been demonstrated [13]. Vertical transmission occurs when the virus gains access to fetal blood by direct placental infection or by fetal swallowing or aspiration of infected amniotic fluid.

RNA viruses can also infect the placenta often without causing characteristic histopathology. Exceptions include Hofbauer cell hyperplasia, chronic histiocytic intervillositis, and massive perivillous fibrin deposition (Supplementary Materials, Table 1). To date, a characteristic placental pathology has not been clearly demonstrated in placentas exposed to SARS-CoV-2. Three series that describe the placental pathology of placentas from COVID-19 patients show disparate results but suggest that coagulopathic findings might be common [14, 15, 16]. Another three cases have been described in which chronic histiocytic intervillositis was associated with placental infection and apparent vertical transmission [9, 10].

The question of whether SARS-CoV-2 infects the placenta is best answered by identifying cases with cellular evidence of viral infection. PCR detection of virus in placental homogenates or swabs is not definitive demonstration of placental infection as they may be contaminated by maternal cells. In addition, demonstration of tissue expression of ACE2 and TMPRSS2 would suggest the capability of the virus to infect the placenta and then possibly the fetus. Herein, we describe 19 placentas from mothers with COVID-19 studied for gross and histopathologic findings, viral expression by in situ hybridization (ISH) and immunohistochemistry (IHC), and ACE2 and TMPRSS2 expression by IHC. We find no specific gross or histopathologic findings in this cohort of COVID-19 exposed placentas. We found two cases of viral infection in the villous trophoblast. We demonstrate that ACE2 is expressed in a membranous pattern in the ST of the chorionic villi. We found that this expression pattern is biased toward the stromal side of the ST, away from the maternal lakes of the placenta. There is also membranous ACE2 expression in the cytotrophoblast (CT) and the EVT. No villous stromal cells, including Hofbauer cells, express ACE2. We demonstrate TMPRSS2 expression is weak and present in the villous endothelium and only rarely in the ST. We propose that these findings explain the limited placental and congenital infection by SARS-CoV-2.

Methods

Case acquisition

With institutional review board approval (IRB2020P001116 and IRB2020P001001) and research support agreement (RSA2020A005296), the pathology department databases at the Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH), and The Beth Israel Deaconess Medical Center (BIDMC), in Boston, were searched for placentas with the clinical history of “COVID-19-positive” or “coronavirus-positive” from March 1, 2020 to May 15, 2020. Positive cases were then verified by reviewing the clinical history for laboratory values through healthcare records (EHR) at each institution. In total 19 maternal test positives were identified and were included in the study. One negative test was retained as a negative control (MGH3). RNA testing for SARS-CoV-2 was performed on nasopharyngeal swabs using FDA-cleared commercial assays performed according to the manufacturers' instructions.

We used three sets of controls for this study (Table 1 ). First, although the specificity of our probe for the ISH has been demonstrated in pulmonary tissues [17], we sought to control for its specificity in the placenta. Ten placentas of COVID-19 negative mothers (delivered either before the pandemic or with negative tests) with clinical histories focusing on infections by an RNA virus (one case each of Zika exposure, HIV infection, and Hepatitis C infection), two cases of intrauterine fetal demise, and with histopathologies associated with congenital infections and coagulopathies (one case each of high stage and grade acute chorioamnionitis, high grade maternal vascular malperfusion (MVM), high grade fetal vascular malperfusion (FVM), high grade villitis of unknown etiology (VUE), chronic histiocytic intervillositis, and multiple intervillous thrombi) were identified from the pathology database using this diagnostic terminology and used as this set of controls. In addition, we used 122 historic “normal” controls from uncomplicated term deliveries (Table 1) to determine the background prevalence of placental histopathologic findings in Boston. These controls were pulled from 2000 to 2004 and were examined for the sole indication of maternal group B streptococcal (GBS) positivity by clinical history. Finally, we included “pathologic” controls identified in a database of placentas from neonates with a clinical diagnosis of hypoxic ischemic encephalopathy (HIE). This HIE database includes 130 placentas examined over 2 decades and includes late preterm and well as term neonates (Table 1). All control placentas were obtained from the MGH.

Table 1.

Controls.

Control category	Number of placentas examined	Average maternal age in years (range)	Average gestational age in weeks + days (range)	Average placental weight percentile {[32], #136} (range)
For ISH probe specificity	10	31 (24–38)	37 + 5 (31 + 6–40)	~34th (<10→90)
“Normal” controls = only GBS+ as indication for placental examination	122	28 (16–40)	39 + 6 (37–41 + 4)	~34th (<10→90)
“Abnormal” controls = placentas from neonates with clinical diagnosis of HIE	130	31 (16–44)	39 + 4 (33 + 6–43)	~30th (<10→90)

GBS group B Streptococcus, HIE hypoxic ischemic encephalopathy, ISH in situ hybridization.

Pathologic evaluation

All placentas were examined for gross and histologic findings at their respective institutions following the Amsterdam Consensus Statement guidelines [18]. Pathologic diagnoses were rendered by experienced perinatal pathologists (DJR, BQ, JLH, CS) following published criteria [11] categorized as shown in Supplementary Materials, Table 2.

Immunohistochemistry and ISH

Formalin fixed and paraffin embedded (FFPE) blocks from each case and the control were chosen to include membranes, umbilical cord, and full thickness parenchyma. Five-micron serial sections were taken and divided for immunohistochemical (IHC) or ISH studies.

Immunohistochemistry was performed using an automated stainer (Bond-III; Leica Microsystems Bannockburn, IL) with ACE2 Monoclonal Antibody (clone CL4035 [1:15,000], Thermo Fisher Scientific, Waltham, MA), TMPRSS2 antibody (Clone PA5-83286 [1:1,000] Thermo-Invitrogen, Carlsbad, CA), and SARS Nucleocapsid Protein Antibody (clone NB100-56576 [1:300], Novus Biologicals, Littleton, CO) in accordance with the manufacturer's recommendations.

SARS-CoV-2 RNA ISH was performed using RNAscope® 2.5 LS Probe-V-nCoV2019-S Cat No. 848568 and, RNAscope® 2.5 LS Reagent Kit-RED Cat No. 322150 Advanced Cell Diagnostic (ACD), on automated BondRx platform (Leica Biosystems). Five-micron thick sections of FFPE placental tissues were used including umbilical cord, membranes, and full thickness parenchyma. All the steps from baking for 1 h at 60 °C to counterstain with hematoxylin were done on BondRx machine. RNA unmarking is done using Bond Epitope Retrieval Solution 2 for 15 min at 95 °C followed by protease treatment for 15 min and probe hybridization for 2 h. Signal was amplified by series of signal amplification steps followed by color development in red using (Bond Polymer Refine Red Detection, Leica) in the forms of red dots. Specificity of the probe has been previously described [17] but was reinforced with ten placentas from COVID-19 mothers as described above.

Outcomes

We describe the histopathology of placentas exposed to maternal COVID-19 infections and compare our findings with published prevalence's and the two sets of selected controls. Viral infection of the placenta is examined by RNA and protein expression. Viral receptor and cofactor expression by IHC are provided. Data presented include limited clinical variables.

Role of the funding sources

The sponsors of this study played no role in study design, data collection, methods, data analysis, data interpretation, or manuscript preparation. The senior author had full access to all the study data and takes final responsibility for the decision for manuscript submission.

Results

Clinical findings

Clinical variables are presented in Table 2 . Maternal age at delivery averaged 31 years (range 22–42 years, median 32 years) and most were multigravidas (16/19, 84%). All births except two (MGH2 and MGH11) were singletons. The maternal COVID-19 test was performed peripartum on all cases within an average of 3 days before delivery (range 9 days ante partum–5 days post partum). The gestational age at delivery averaged 35 3/7 weeks (range 22–41 1/7 weeks, median 36 4/7 weeks). Indications for delivery included maternal (spontaneous labor (n = 4), respiratory compromise from COVID-19 (n = 6), and preeclampsia (n = 3)), and fetal (abruption (n = 2), and nonreassuring fetal testing (n = 4)). The cesarean delivery rate was 60% with most performed for fetal indications. Most neonates did well in the early perinatal period except for a few cases with complications of prematurity (n = 8 of 21). One infant had complications related to intrapartum compromise (MGH8).

Table 2.

Cases clinical features.

Case	MA	G	P	GA at delivery (weeks + days)	Days from COVID+ test to delivery	Maternal COVID-19 symptoms peripartum	Indication for delivery	Route of delivery	Birth outcome	Neonatal course	Fetal/Infant COVID test results
MGH2	24	1	0	30	3	Intubated/Ventilated	Twins NRFHT Maternal respiratory status	CS	Livebirth X2	Both twins to NICU with complications of prematurity	Each twin Negative X2
MGH3	25	1	0	33 + 4	PP day 5 negative	No symptoms	PPROM	VD	Livebirth	Benign	Negative X2
MGH4	33	3	0	40 + 1	7	Mild SOB, myalgias	Decreased fetal activity NRFHT	CS	Livebirth	Benign	Negative X1
MGH8	33	3	2	37 + 4	0	No symptoms	Abruption, DIC required gravid Hysterectomy	CS	Livebirth	NICU for neonatal encephalopathy	Negative X1
MGH9	32	2	0	36	PP day 1	Anosmia, fever, chills, fatigue	Placental previa, vaginal bleeding, labor	CS	Livebirth	Benign	Positive at 24 and 48 h of life
MGH10	37	5	3	22	7	Fever, cough, head- ache	IUFD	VD	Stillbirth	Stillbirth	Not performed
MGH11	29	2	1	30 + 6	0 (H/O +test at 23 weeks GA then −test X2 but + on admission to LD)	Anosmia	Twins PPROM/PTL NRFHT 1 twin breech	CS	Livebirth X2	Both admitted to the NICU with respiratory complications related to prematurity	Each twin Negative X2
MGH12	32	2	1	38 + 5	3	No symptoms	Term labor	VD	Livebirth	Benign	Negative X1
MGH13	25	4	2	36 + 3	3	SOB, fever, cough, pneumonia on CXR	Maternal respiratory Status, NRFHT	CS	Livebirth	Benign	Negative X1
MGH14	22	1	0	41 + 1	0	No symptoms	Spontaneous labor	VD	Livebirth	Benign	Negative X1
BWH2	25	2	1	39 + 5	3	No symptoms	Spontaneous labor	VD	Livebirth	Benign	Negative X1
BWH4	26	2	1	37 + 2	2	Rhinorrhea, cough	Cholestasis	VD	Livebirth	Benign	Negative X1
BWH5	39	4	3	37 + 1	0	Fever, low oxygen saturation in labor	T2DM	CS	Livebirth	Macrosomia Benign	Negative X1
BWH6	33	1	0	38 + 3	0	No symptoms	PIH, FGR	VD	Livebirth	Benign	Negative X1
BWH9	35	4	0	38 + 3	3	No symptoms	PET	CS	Livebirth	Benign	Negative X1
BIDMC1	36	3	0	37.2	8	DOE, cough	cHTN, GDM	CS	Livebirth	Benign	Not performed
BIDMC2	34	3	1	35.3	7	Respiratory distress on 4 L O2 then intubated immediately PP, hypoxemia, cough	Maternal respiratory status, breech	CS	Livebirth	NICU for hypoglycemia and prematurity	Negative X1
BIDMC3	28	2	1	31.6	9	Fever, “worsening respiratory symptoms” no supplemental O2, cough, malaise, myalgia, rash	Maternal respiratory status	CS	Livebirth	NICU for respiratory distress, rash, and prematurity	Negative X1
BIDMC4	42	2	0	29.3	1	Fever, no respiratory symptoms	Chronic abruptio, PPROM, decreased fetal activity	VD	Livebirth	NICU for respiratory distress and prematurity	Negative X1
BIDMC5	28	2	1	35.5	5	Respiratory difficulty on 2 L O2, cough, fever, hemoptysis, sore throat, myalgia	Maternal COVID symptoms, Breech	CS	Livebirth	Mild pulmonary immaturity	Negative X1

cHTN chronic hypertension, CS cesarean section, CXR chest X-ray, DIC disseminated intravascular coagulation, DOE dyspnea on exertion, FGR fetal growth restriction, GDM gestational diabetes mellitus, H/O history of, HSV herpes simplex virus, IUFD intrauterine fetal demise, L liter, NRFHT nonreassuring fetal heart testing, PET preeclampsia, PIH pregnancy induced hypertension, PP post partum, PPROM preterm premature rupture of membranes, SOB shortness of breath, T2DM type 2 diabetes mellitus, VD vaginal delivery.

The maternal COVID-19 respiratory status was mild except for in five women who had severe symptoms requiring supplemental oxygen, including one who was being mechanically ventilated at the time of delivery (MGH2) and one immediately after delivery (BIDMC2). Only one neonate who was tested, tested positive for SARS-CoV-2 24 h (MGH9) [19]. There were no maternal or neonatal deaths in our series, but one (MGH10) was from a 22 weeks gestation intrauterine fetal demise.

Placental gross and histopathology

Placental pathologic, immunohistochemical, and ISH findings are presented in Table 3 . Placental gross and histopathologic features compared with the two control groups are summarized in Supplementary Materials, Table 3. Overall we found no specific gross or histopathology in placentas associated with exposure to SARS-CoV-2 (Table 3). Grossly there were frequent umbilical cord insertional anomalies (30%, above the background reported prevalence of from 0.1 to 15% [20]). Looking at the histopathology by category (Supplementary Materials, Table 2), we found any MVM at 25% (5 of 19 cases), which was similar that present in the “normal” controls (25% prevalence) and the “abnormal” controls (15% prevalence) or a reported background prevalence of 33% [21]. Three of our MVM cases were low grade and two were high grade (MGH8 and MGH14) neither of which were associated with hypertensive disorders. These two cases had decidual arteriopathy (Fig. 1 ). Although there were no cases of massive perivillous fibrin deposition, one case had multifocal increased perivillous fibrin but not to the diagnostic criteria of MPFD (MGH14, Fig. 1) [22]. FVM was present in four cases (20%) but one was associated with an intrauterine fetal demise (MGH10) and, on review, was considered a postmortem pathology. Excluding this case, the 15% prevalence of any FVM in our COVID-19 associated placentas is within the published prevalence of FVM at from 7 to 20% [23]. The case prevalence is higher than the prevalence present in our “normal” controls (5%), but similar to that present in our “abnormal” controls (17%). Thirty percent of cases were classified in the Infe COVID category but only one case was high grade (BWH5, Fig. 1). This prevalence is higher than that seen in our “normal” controls but less than in the “abnormal” controls. All the Infe COVID-19 associated cases were acute chorioamnionitis and four of the sixes cases had a fetal inflammatory response. Inflammatory pathologies were seen in 15% (3 of 19 cases) and all were either low grade or ungradeable. One case had focal Hofbauer cell hyperplasia (MGH9) and one case had histiocytic intervillositis (MGH12, Fig. 1), but not of a degree for a diagnosis of chronic histiocytic intervillositis [24]. There was one case of VUE (5%), within the published prevalence of 5–15% [25]. Our 15% prevalence of any inflammatory pathology compares with any inflammatory pathology in the “normal” controls (25/122, 20%) or the “abnormal” controls (15/130, 12%). If only scoring the Infl-HG placentas, we found 2 in 122 “normal” controls (1.6%) and 4 in 130 “abnormal” controls (3%), both above our cases at 0%.

Table 3.

Pathologic features.

Case	GA	Placental weight (g)	Weight percentile [32]	Gross pathology	H&E microscopic pathology	H&E microscopic category/grade (see Table 2)	ACE2 IHC	TMPRSS2 IHC	nCapsid IHC	SARS-CoV-2 RNA ISH
MGH2	30	473 combined	~25th	DDTP, circumvallation both twins	Both twins with acute chorioamnionitis (maternal stage 1, grade 1) Twin B with focal AVV (FVM, LG)	FVM/LG Infe/LG Gross	ST—circumferential EVT CT Scattered decidua parietalis cells	Negative	Negative	Negative
MGH3	33 + 4	336	~10th	Marginal insertion of the umbilical cord	Subchorionic thrombus	Other/LG Gross	ST—primarily biased CT EVT Scattered decidua parietalis cells	Negative	Negative	Negative
MGH4	40 + 1	403	<10th	None	Meconium pigment Acute chorioamnionitis (maternal stage 2, grade 1) with fetal inflammatory response (fetal stage 1, grade 1) Membrane myometrial fibers	Infe/LG Hypo/LG Other/LG	ST—biased CT EVT Scattered decidual parietalis cells	Focal in muscularized stem villous vessels walls	Negative	Rare ST and CT
MGH8	37 + 4	428	~25th	Green discolored, 1 cm central firm parenchymal mass	Meconium pigment Decidual arteriopathy with acute atherosis Single small central placental infarct, usual type Patchy increased perivillous fibrin	MVM/HG Hypo/LG	ST—primarily biased, some circumferential CT EVT Scattered decidua parietalis cells	Weak in villous endothelium	Negative	Negative
MGH9	36	469	~45th	Hypercoiled umbilical cord, central parenchymal mass not measured	Single central placental infarct, usual type with peripheral increased perivillous fibrin, Hofbauer cell hyperplasia, focal	MVM/LG Infl/LG Gross	ST—circumferential CT EVT Maternal endothelium Scattered decidua parietalis cells	Spotty weak villous endothelium	Multiple foci of strong staining in ST	Multiple foci of strong staining in ST
MGH10	22	54	<10th	None	Postmortem AVV, VSK, SVO Chorangiomatosis Necrotizing acute chorionitis Plasma cell deciduitis	FVM/HG- postmortem Infe/LG Infl/LG Other/HG	ST—stromal biased CT EVT	Negative	Negative	Negative
MGH11	30 + 6	524	~30th	Fused DDTP, velamentous cord insertion twin A	Patchy chorangiosis	Hypo/LG Gross	ST—stromal biased EVT Decidual parietalis stromal cells and maternal endothelium			Negative
MGH12	38 + 5	522	~60th	Green discolored membranes, Rightward coiled umbilical cord	IMFD Meconium pigment VUE, ungradeable Intervillositis	FVM/LG Infl/LG Hypo/LG Gross	ST—stromal biased CT EVT			Negative
MGH13	36	487	~65th	None	Meconium pigment IMFD Subchorionic thrombus Decidual arteriopathy, hypertrophic type Adherent basal plate myometrial fibers	FVM/LG MVM/LG Other/HG	ST—stromal biased EVT Decidual parietalis stromal cells and maternal endothelium			Negative
MGH14	41 + 1	353	<10th	5 firm parenchymal regions up to 1.6 cm in size	Multifocal regions of increased perivillous fibrin	MVM/HG	ST—stromal biased CT EVT			Negative
BWH2	39 + 5	518	~50th	Marginal insertion of the umbilical cord	Acute chorioamnionitis with fetal (maternal stage 1, grade 1) with fetal inflammatory response (fetal stage 1, grade 1)	Infe/LG Gross	ST—circumferential with some stromal biased CT EVT Maternal endothelium Decidua Scattered decidua parietalis cells	Negative	Negative	Negative
BWH4	37	595	>90th	Marginal insertion of the umbilical cord	Acute chorioamnionitis (maternal stage 1, grade 1) Meconium pigment Fetal normoblastemia Adherent myometrial fibers	Infe/LG Hypo/HG Other/LG Gross	ST—stromal biased CT EVT Maternal endothelium Decidua	Negative	Negative	Focal positive maternal endothelial cells in decidua parietalis Placenta-negative
BWH5	37 + 1	797	>90th	True knot of the umbilical cord	Acute chorioamnionitis (maternal stage 1, grade 2) with fetal inflammatory response (fetal stage 2–3, grade 2) Intervillous thrombus with associated placental infarct	Infe/HG Other/LG Gross	ST—stromal biased CT EVT Maternal endothelium Rare umbilical artery endothelial cells Decidua	Weak focal villous endothelial cells and stem vessel smooth muscle	Negative	Negative
BWH6	38 + 3	477	~45th	Rightward coiled umbilical cord	Decidual arteriopathy	MVM/LG Gross	ST—mix of circumferential and stromal biased CT EVT Scattered decidua parietalis cells	Negative	Negative	Negative
BWH9	38 + 3	330	<10th	Velamentous insertion of the umbilical cord	None	Gross	ST—circumferential CT EVT Decidua	Weak in villous endothelium	Negative	Negative
BIDMC1	37 + 2	526	~75	None	None	None	ST—stromal biased EVT Decidua	Weak in villous endothelium, negative in membranes and umbilical cord	Negative	Negative in placental tissues
BIDMC2	35 + 3	454	~60	None	None	None	ST—stromal biased EVT Decidua	Weak in villous endothelium, Umbilical cord endothelium and very weak and patchy in the ST	Negative	Negative in placental tissues
BIDMC3	31 + 6	290	~10th	None	Villous edema Subchorionic thrombus	Hypo/LG Other/LG	ST—stromal biased EVT Decidua	Very weak in villous endothelium, negative in membranes and umbilical cord	Negative	Negative in placental tissues
BIDMC4	29 + 3	363	>90th	None	Acute chorioamnionitis (maternal stage 1, grade 1) with fetal inflammatory response (fetal stage 1, grade 1) Villous edema	Infe/LG Hypo/LG	ST—stromal biased, rare circumferential EVT Squamous metaplasia of amnion on umbilical cord	Weak in villous endothelium, negative in membranes and umbilical cord	Negative	Negative
BIDMC5	35 + 5	518	~80th	Marginal insertion of the umbilical cord	None	Gross	ST—stromal biased EVT Decidua	Weak in villous endothelium, negative in membranes and umbilical cord	Weak and focal in ST	Negative in placental tissues

AVV avascular villi, CT cytotrophoblast, DDTP diamniotic dichorionic twin placenta, EVT extravillous trophoblast, HG high grade, IHC immunohistochemistry, ISH in situ hybridization, LG low grade, ST syncytiotrophoblast, SVO stem vessel obliteration, VSK villous stromal-vascular karyorrhexis, VUE villitis of unknown etiology.

Fig. 1.

H&E Histopathology of COVID-19 exposed placentas.

a Decidual arteriopathy with acute atherosis (MGH8), 10X. b Histiocytic intervillositis (MGH12), 40X. c Fetal inflammatory response in the umbilical vein extending into Wharton's jelly (BWH5), 10X. d Increased perivillous fibrin (MGH14), 10X.

ACE2 expression

ACE2 was expressed in the ST in a membranous pattern with a polarity such that expression was strongest at the membrane adjacent to the CT and villous stroma (Table 3, Fig. 2 ). In many cases, the expression was restricted to the stromal side membrane (in 14 of the 20 cases total). ACE2 was also strongly expressed in the villous CT usually in a circumferential membranous pattern and present in a membranous, and occasionally in a cytoplasmic pattern, in scattered EVT in the decidua basalis and chorion laeve (Fig. 2). Maternal vessels showed strong staining present in endothelial cells and pericytes in the decidua parietalis (when present, Fig. 2). No ACE2 staining was present in villous stroma, Hofbauer cells, amniotic epithelium, or fetal endothelium.

Fig. 2.

ACE2 and TMPRSS2 expression.

Immunohistochemical stains for ACE2 at 60X showing case MGH3 (a, negative control) and case MGH9 (b) show membranous expression of ACE2 in syncytiotrophoblast and cytotrophoblast. Note the polarity of staining in a such that the strongest staining is on the villous stromal side of the syncytiotrophoblast (arrow) compared to the maternal lake side (arrowhead). This polarity is not present in case MGH9 as stain is present on the maternal lake side (arrowhead) and villous stromal side (arrow) in b. A syncytiotrophoblastic knot shows cytoplasmic staining in case MGH9 (arrow in b). This finding was focally present in all cases. Immunohistochemical stains for TMPRSS2 at 20X (case MGH3, c) and 40X (case BIDMC2, d). No stain is present in case MGH3 (c, negative control) but weak cytoplasmic staining is preset in the villous endothelium (arrow) and weak membranous staining in the ST (arrowhead) in case BIDMC2 (d). e ACE2 expression in the decidual parietalis maternal endoderm/pericytes (BWH4), 20X. f ACE2 expression in the EVT in the decidua basalis (BIDMC3), 20X.

TMPRSS2 expression

In rare cases, TMPRSS2 expression was weakly positive in a cytoplasmic pattern in the villous endothelium (Fig. 2 and Table 3). Only one case had TMPRSS2 staining in a membranous pattern very weakly and in a patchy distribution in the ST (BIDMC2, Fig. 2). Most cases were negative for any detectable expression of TMPRSS2.

Viral expression via IHC or ISH

Most cases were negative for any viral protein (18 of 19 by IHC) or RNA (17 of 19 by ISH) (Table 3) in the placenta. ISH probe controls were all negative. Rare weak expression was detected by ISH in the maternal endothelium in the decidua parietalis in few cases. One case (MGH9) showed robust expression by both techniques in a patchy distribution in the ST (Fig. 3 ). One other case (MGH4) had very focal ST and CT expression only by ISH (Fig. 4 ). Neither showed FVM. MGH9 did show low grade MVM and Infl pathology (Table 3).

Fig. 3.

Viral expression via IHC and ISH.

Left column of images from MGH3 (negative control). Right column of images from MGH9. H&E (a, b), immunohistochemical stains for nCapsid (c, d), and in situ hybridization for viral RNA (e, f), 20X.

Fig. 4.

Viral expression via ISH in MGH4.

Focal expression in the syncytiotrophoblast and cytotrophoblast at 40X (left panel) and 60X (right panel).

Discussion

Although there have been many reports of infants born to mothers tested to be SARS-CoV-2 positive [3, 7, 26, 27, 28, 29], there are only rare case reports of probable vertical transmission [4, 5, 9, 10, 30, 31]. This suggests that SARS-CoV-2 either rarely infects the placenta or is prevented from transmission despite placental infection. We show that SARS-CoV-2 can infect the placental ST and CT (Figs. 3 and 4). In addition, we show that ACE2, the receptor for SARS-CoV-2, is expressed in a membranous pattern in the ST and CT of the villi, and in both a membranous and cytoplasmic pattern in the EVT in the chorion laeve and decidua basalis (Fig. 2). We also report a unique polarized expression of ACE2 such that in most cases ST expression is strongest, and sometimes only, present in the cell membrane internal, or stromal, side of the trophoblast (Fig. 2). In addition, we find that TMPRSS2 is rarely expressed in the trophoblast and is expressed only weakly in the villous endothelium (Fig. 2).

Although we had no characteristic placental pathology in our cases from COVID-19 exposed placentas, we did see a spectrum of pathologies (Table 3). Interestingly we saw only one case each of chronic villitis, intervillositis, and increased perivillous fibrin. Except for an increase in gross pathologies, the prevalence of the other categories was within our control groups and published series. The gross pathology findings are difficult to explain but are unlikely to be related to SARS-CoV-2 exposure.

To the authors knowledge, there are seven reports of placental findings related to SARS-CoV-2 exposure (Supplementary Materials, Table 1). In Baergen and Heller's report [14], they that found 10 of 20 exposed placentas had FVM. Although not graded in their report, by description it is likely that four were high grade. Our prevalence of 15% of FVM (all low grade) is higher than our “normal” controls and this may be a real increase, similar to prevalence in our “abnormal” controls. The manuscript by Shanes et al. [16] describes an increased prevalence of MVM in their series of 16 placentas delivered to women with COVID-19. Although there were only two cases with MVM in their series of 16, which was significantly above their robust controls. There is one manuscript [15] that describes the placentas from three COVID-19 infected mothers in China. All three placentas were described as having increased perivillous fibrin. Baud et al. [4] published a case of apparent placenta infection in a 19 weeks intrauterine fetal demise. The infection was detected by placental homogenate and swab PCR (which we believe may be contaminated by maternal tissue). Fetal tissues were negative for SARS-CoV-2. The figures demonstrate mild acute chorioamnionitis with a fetal inflammatory response. Although the authors conclude that there was increased perivillous fibrin and syncytial knots (both features of MVM), the image is not convincing. In our opinion, the findings are more consistent with the effects of retention of an intrauterine fetal demise. Our series found MVM in 25% of cases but that was within our control prevalence. Kirtsman et al. [5] described CHI in a placenta from a case of potential vertical transmission. Three of these seven reports found features that suggest a coagulopathic process. Although we did see MVM and FVM in our series, we did not see them increased over published prevalence's or our two sets of controls. Two recent case reports describe placental infection by ISH in three cases [10] and in one case [9]. Both of these reports found infection in the ST as did we. Hosier et al. [9] also demonstrated virus in the ST by electron microscopy. Three of these four cases demonstrated histiocytic intervillositis, as we saw in one of our cases, but not in either of our two cases with infection. We believe that our data and the published literature has not definitively identified a histopathologic footprint of SARS-CoV-2 infection of the placenta or features characteristic of exposure without infection.

We expected an increase in chronic inflammatory pathologies, particularly chronic villitis or chronic intervillositis, in these exposed placentas given what has been reported in other RNA viral infections (Supplementary Materials, Table 1). We did not see this in our cases. In our series, there are three cases with a chronic placental inflammatory process, but none are high grade. Although this represents a prevalence of 15% overall, there was only one case of chronic villitis (VUE, ungradeable) at 5%, within the accepted background prevalence published at from 5 to 15% [25]. In the published literature, there are only case reports identifying a chronic inflammatory process, three identifying intervillositis [5, 9, 10]. Intervillositis was seen in one of our cases (and was not one of the two cases with demonstrable placental infection) but has not been described in other series [14, 16]. Whether it is a true marker for SAR-CoV-2 placental infection needs more study.

Our morphologic study is limited in that we did not use optimal controls. We believe that the best controls would have been placentas delivered to women with COVID-19 symptoms (e.g., hypoxia) but SARS-Cov-2 test negative. This should be done to definitively identify if coagulopathic or inflammatory pathologies are increased in this population. In our one placenta from a symptomatic but COVID-19 test negative woman, the placenta showed a subchorionic thrombus (MGH3).

In summary, we show that ACE2 is expressed in the trophoblast of the placenta with a polarized membranous pattern in the ST. We also show that TMPRSS2 is expressed weakly mainly in the chorionic villous endothelium. We demonstrate SARS-CoV-2 virus infection of the ST and CT. This is conclusive evidence of placental infection and therefore confirms the possibility of vertical transmission. As we have no definitive cases of congenital infection, these data suggest that placental infection may not always equate with vertical transmission.

Author contributions

All authors had full access to the data in this report and take responsibility for its integrity and accuracy. JLH, BQ, and DJR were responsible for the concept and analysis of this study. BD, TH, CS, and DS contributed cases and reports. The HIE database is maintained by SVB. Authors JLH, BQ, and DJR were responsible for drafting this manuscript but all authors had input into the final version. DTT, VD, and ND were responsible for the ISH studies. MM-K was responsible for optimizing the IHC studies.

Compliance with ethical standards

Conflict of interest

DTT has received consulting fees from Merrimack Pharmaceuticals, Ventana Roche, Foundation Medicine, Inc., and EMD Millipore Sigma, which are not related to this work. DTT is a founder and has equity in PanTher Therapeutics and TellBio, Inc., which is not related to this work. DTT is cofounder and own equity in ROME Therapeutics, which is not related to this work. Parts of this work were supported by ACD-Biotechne (ND, VD, DTT). DTT's interests were reviewed and are managed by Mass General Brigham in accordance with their conflict of interest policies. MM-K has received consulting fees from H3 Biomedicine and AstraZeneca and institutional grant support from Novartis, all of which are not related to this work. DJR received royalties from UpToDate and Cambridge University Press as an author, not related to this work. All other authors declare no competing interests.